To facilitate development of Taiwan’s biomedical industry, the government proposed a “biomedical industrial innovation promotion program (BIIP)” in November 2016, with the central theme of “local, global and future links” to position Taiwan as the hub of biomedical research and development (R&D) in the Asia-Pacific region. By 2025, the goal is to develop 20 new drugs and have 80 different high-value medical devices on the international market, creating an NT-trillion-dollar industry offering a wide range of quality products.

BIIP includes four action plans:

A: to build a comprehensive ecosystem

B: to integrate innovative business clusters

C: to connect global market resources

D: to promote specialized key industries

Among them, Action A "build a comprehensive ecosystem" will be enhanced by focusing on 6 diections to proceed: personnel trainig, capital, topic selection, intellectual property, regulations, and resources. Therefore, Commercialization Center is established to consolidate resources, incubate startups, and strengthen technical support platforms for industrial and academic research.

BioMed Commercialization Center (Drug Division), BMCC|Drug, under BIIP/BDB, launches in April 2017, and is located in the Nangang National Biotechnology Research Park (NBRP).



Drug discovery and development is a time-consuming, expensive, and high risk process. It takes at least 10 years to develop a new drug from initial discovery to market, with an average R&D cost of $2-6 billion.


In Taiwan, the research stage from drug discovery to preclinical studies are usually conducted in the universities or research institutes, further development stage heavily depends on biotech companies which are small to medium entities often with scarce resources. These companies with small capitals and lack of expertise makes them vulnerable in the drug R&D process and reluctant to license drug or technologies discovered from the academia without authentic evaluation from a trusted organization. Therefore it is essential for an experienced team with adequate knowledge and provides necessary resources to identify the obstacles and bridge any gaps in the commercialization process in order to facilitate the technology transfer smoothly.




The establishment of BioMed Commercialization Center (Drug Division, BMCC|Drug) is to provide an integrated platform to overcome the bottleneck found in the development and commercialization of pharmaceuticals for academia and industries.


The integrated platform mainly includes 6 capabilities: high-potential project selection, intellectual property layout, start-up & incubation, technology commercialization, international cooperation, and knowledge diffusion & personnel training.



The BioMed Commercialization Canter (Drug Division, BMCC|Drug) offers an extensive array of services to academia and industries. Our highly skilled team currently supports universities, research entities and private companies through a wide range of services including technology assessment, market analysis, IP portfolios management, technology licensing, patent & regulatory consultation, business development consultation, innovation & incubation, and project management.


Through many years of experience assisting different sectors of the industries, BMCC|Drug is dedicated to facilitate technology transfer, licensing-out, co-development, and spin-off companies. The ultimate goal is to facilitate commercialization of drugs and technologies in order to strengthening the economy and creating job opportunities.